One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo, suggests new findings. The research, led by scientists from Imperial College London and published in the Journal of the American Medical Association, studied three types of diabetes treatment: sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like
Immunotherapies are treatments that stimulate a patient’s immune cells to attack tumors. They can be very effective in melanoma—a common and aggressive form of skin tumor—but nonetheless fail in the majority of patients. To address this, researchers are trying to identify the factors that enable successful immunotherapy, as well as those that may limit it.
Adding the monoclonal antibody drug trastuzumab—already used to treat certain breast cancers—to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small phase II trial of the regimen, testing its safety and value.
On-site testing of ‘party drug’ pills could reduce the harms caused by drug use and potentially save lives, according to an independent review of Australia’s National Drug Strategy, published in the open access Harm Reduction Journal. Dr Andrew Groves at Deakin University, Australia, examines evidence in support of pill testing to reduce fatalities caused by
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok